Fig.1. The dose of GH administered to patients in different age groups after 1 year of GH replacement therapy. Data are shown as mean, median and 10th-90th.

Slides:

Advertisements

Similar presentations

Lung Function Nutrition FEV 1 Percent Predicted vs BMI Percentiles Patients

Advertisements

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Short Stature in Noonan Syndrome: Demography and Response to Growth Hormone Treatment in KIGS Barto J Otten KIGS 10 Year Book, 1999.

Continuing the Treatment of Growth Hormone Deficiency During the Transition from Childhood into Adulthood Michael B Ranke and John P Monson KIGS 10 Year.

Final Height Following Growth Hormone Treatment of Idiopathic Growth Hormone Deficiency in KIGS Wayne S Cutfield, Anders Lindberg, Pierre Chatelain, David.

Growth Hormone Treatment of Children with Prader-Willi Syndrome as Reported to KIGS: First-Year Growth Hormone E Martin Ritzén KIGS 10 Year Book, 1999.

QTc, ms Distribution of QTc in normal girls aged 7 to 17 years (control) and girls of the same age with TS. The wide bars indicate the median, and the.

Norwegian register for general thoracic surgery.

The natural history of Turner syndrome and its associated problems

Features of adult GH deficiency Improved by GH replacement?

Adverse Events - Demographics

0.24→0.37 mg/kg/week (▲) and 0.37 mg/kg/week ().

ERT, estrogen replacement therapy

Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study - DOI: / Fig. 1.

Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World.

Long-term Pegvisomant treatment outcomes in Patients with Acromegaly: Spanish ACROSTUDY data A.Pico1, E.Venegas2, T.Lucas3, C. Alvarez-Escolá4, J.A. García.

Fig. 1. Serum levels of IGF-I vs

CPR 1.1. Identifying Patients and Initiating Evaluation

UK Renal Registry 19th Annual Report

Efficacy and Side Effects of Granulocyte Collection in Healthy Donors

Fluid retention symptoms Miscellaneous symptoms

MicroRNA221-3p modulates Ets-1 expression in synovial fibroblasts from patients with osteoarthritis of temporomandibular joint J. Xu, Y. Liu, M. Deng,

Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients Breast Care 2016;11: DOI: / Fig. 1. Strategies.

The Impact of Chronic Pain on Life in the Household

Population Structures

FIG. S4. IL-8 IL-10 IL-12 IL-6 TNF IFN-γ

Volume 72, Issue 5, Pages (September 2007)

GH peak (µg/l) Regression analysis of the GHRH+GHRP-6-elicited GH peaks plotted against body mass index (BMI), in 366 subjects with no endocrine pathology.

A B Yeom Supplementary Fig.2

Major physical anomalies according to parental origin of retained Xp

#significant difference versus baseline (P<.05).

Effects of 5 yr of GH substitution in 118 GH-deficient adults on serum concentrations of TC, HDL-C, LDL-C and TG as well as on blood glucose, serum insulin.

Bones mass (BMC) and standing height in patients with COGHD compared with normal Russian adults. All values are compared with results obtained.

Relationship between karyotype and basal characteristics at GH start

Baseline Data Proper Re-identification

A B GH and IGF-1 action on the effect of oral estrogen Pituitary Gland

Controls r=-0.82; P< GHD r=-0.84; P< Mean IMT (mm)

An evaluation strategy for potential QTc prolongation with chronic azithromycin therapy in cystic fibrosis Patrick John Lenehan, Craig M. Schramm, Melanie.

Control Subjects MPHD Patients Control Subjects MPHD Patients

No GH (n=19) Treated with GH (n=67) Mean (SD) Range Mean (SD) Range

GH dose 12 months of treatment 24 months of treatment Low Medium High

Intrathecal sufentanil and morphine for post-thoracotomy pain relief†

Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: A reconsideration Drucy Borowitz, Daniel Gelfond, Karen.

Fig.1 Simple least-squares regression of the relationship between the log of peak GH concentration on standard GH stimulation tests and serum IGF-1 concentrations.

 Height SDS  Weight SDS

 Gruppe A: 0,033mg WH/kg x die  Gruppe B: 0,067mg WH/kg x die

CPR 1.2.: Evaluation of Anemia in CKD

Height velocity (cm/yr) Height velocity (cm/yr)

Table 6.1.1: Stock and Flow, *based on year of death Year

Brigitte Toro, MSc, Chris J Nester, PhD, Pauline C Farren, PhD

STAI: higher scores reflect more anxiety (scores 20-80).

Sensivity Sensivity Sensivity 100-specify 100-specify 100-specify

Comparison between groups

CI, confidence interval (95%)

Growth rate (cm/yr) Estrogen at age 12 Estrogen at age 15

Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections Barbara Knorr, MDa, Sherry Holland, PhDb, J.Douglas.

Bigna M. Keller, Carmen Casaulta Aebischer, Richard Kraemer, Martin H

Abbildung mod. nach Van Pareren, 2004

Change in LBM (%)‏ LD CD LD CD LD CD

Supplementary Table S2 Correlation between pre-operative plasma miR-451 or miR-486 concentrations and clinicopathologic features in gastric cancer patients.

Traumatic brain injury as a relevant cause of growth hormone deficiency in adults: A KIMS-based study Felipe F. Casanueva, MD, PhD, Alfonso Leal, MD,

1. What animal 2. Male or Female ? 4. Male or Female? Why? Why?

UK Renal Registry 16th Annual Report

Fig. 2. The pain score change in vitamin C group

Absence of a gender gap in survival

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

Minimum effective local anaesthetic dose of isobaric levobupivacaine and ropivacaine administered via a spinal catheter for hip replacement surgery Sell.

Sodium consumption (mg/day) at baseline by demographic characteristics in a cohort of self-referred patients with type 2 diabetes. Sodium consumption (mg/day)

Table 6.1.1: Stock and Flow, Year

* OS >3yr with No Next Line * * * * *

Presentation transcript:

Fig.1. The dose of GH administered to patients in different age groups after 1 year of GH replacement therapy. Data are shown as mean, median and 10th-90th percentiles Females Males n=259 n=171 n=113 n=52 n=217 n=199 n=163 n=83 0,8 0,8 0,6 0,6 GH dose (mg/day) GH dose (mg/day) 0,4 0,4 0,2 0,2 p<0,05 p<0,05 <45 45-55 55-65 >65 <45 45-55 55-65 >65 Age group (years) Age group (years) Abbildung mod. nach Monson, 2003

Fig.2. IGF SDS in patients in different age groups after 1 year of GH replacement therapy. Data are shown as mean, median and 10th-90th percentiles. Females Males n=188 n=125 n=73 n=40 n=146 n=145 n=199 n=65 3 3 2 2 1 1 IGF-1 SDS IGF-1 SDS -1 -1 -2 -2 p<0,05 p<0,05 -3 -3 <45 45-55 55-65 >65 <45 45-55 55-65 >65 Age group (years) Age group (years) Abbildung mod. nach Monson, 2003